Drugs / BI 754111
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03433898 | Feb 2018 → Jul 2023 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03964233 | Jun 2019 → Sep 2024 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03780725 | Jan 2019 → Feb 2020 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT03156114 | Jun 2017 → Mar 2023 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03697304 | Mar 2019 → Dec 2024 | metastatic neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 754111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03697304 ↗ |
| Action | Inhibit | “We generated BI 754111, which bound with high affinity to human LAG-3 and prevented LAG-3 interaction with its ligand, major histocompatibility complex class II.” PMID 35756842 ↗ Jun 2022 |
| Route | Intravenous | “Different dosages of BI 754111 given as an intravenous infusion” NCT03156114 ↗ |